Peter Sever - Concepedia

Author

Peter Sever

Also Known As

Bentley, Amy R., Bis, Joshua C., David Conen, Elizabeth Selvin, Ellen M Schmidt, Francesco P. Cappuccio, Grant, Struan F. A., Helgadottir, A., Hovingh, G Kees, Jukema, J Wouter

340

Publications

47K

Citations

H-Index

137

Concepts

All Affiliations

Imperial College London University of Glasgow Queen Mary University of London William Harvey Research Institute Sahlgrenska University Hospital

About

Peter Sever is an author at Imperial College London specializing in medicine, cardiovascular disease, and hypertension.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	59	15.4K
2	Health Sciences	5	5	286
3	Natural Sciences	2	2	207
4	Engineering	1	1	61
5	Humanities	1	1	13

Peter Sever

145

Publications

25.1K

Citations

H-Index

Page 1

	Year	Citations
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Peter Sever, Björn Dahlöf, Neil R Poulter, The Lancet ThrombosisHypertensionCardiovascular DiseaseHypertensive PatientsMedicine	2003	3.8K
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Björn Dahlöf, Peter Sever, Neil R Poulter, The Lancet HypertensionCardiovascular DiseaseAmlodipine Adding PerindoprilMedicineControlled Trial	2005	2.9K
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Peter M. Rothwell, Sally C. Howard, Eamon Dolan, The Lancet Blood Pressure MonitoringHypertensionVisit-to-visit VariabilityCardiovascular DiseaseAntihypertensive Therapy	2010	1.7K
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Bryan Williams, Thomas M. MacDonald, S. V. Morant, The Lancet	2015	1.2K
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano, Circulation	2019	895
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary Bryan Williams, Neil R Poulter, Morris J. Brown, BMJ HypertensionHeart FailureCardiovascular PharmacologyBlood PressureNon-pharmacological Intervention	2004	847
A saturated map of common genetic variants associated with human height Loïc Yengo, Sailaja Vedantam, Eirini Marouli, Nature	2022	827
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Circulation	2017	731
Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke Peter M. Rothwell, Sally C. Howard, Eamon Dolan, The Lancet Neurology ThrombosisHypertensionCardiovascular DiseaseMedicineAntihypertensive Therapy	2010	677
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension Neil Chapman, Joanna Dobson, Sarah L Wilson, Hypertension HypertensionResistant HypertensionCardiovascular DiseaseMedicineSpironolactone Therapy	2007	621

Page 1